MinervaX
84 employees on LinkedIn · 13 known investors
MinervaX is a biotech company developing prophylactic vaccines, with therapeutic focus areas including immunology and infectious disease. Its work spans vaccine discovery through late-stage clinical development and regulatory approval.
Founders & leadership
P
Per
B
BengtCSO
Investors · 13
Adjuvant Capital✓ verifiedNew York · $10M – $25M
Industrifonden✓ verifiedStockholm · $1.1M – $4.3M
OrbiMed✓ verifiedNew York · $1M – $75M
Pureos Bioventures✓ verifiedPfäffikon
Sanofi Ventures✓ verifiedCambridge · $5M
Sunstone Capital✓ verifiedFrederiksberg
EQT Life Sciences✓ verifiedLuxembourg · $11M – $66M
Novo Holdings✓ verifiedCopenhagen · $1.1M – $54M
LU InnovationLund
Also in the syndicate · 4
LF InvestPureos VenturesSunstone LifeScience VenturesTrill Impact Ventures
Founder mafia
2 people who came through MinervaX went on to found or lead other companies.
In the news
Frequently asked questions
- What does MinervaX do?
- MinervaX is a biotech company developing prophylactic vaccines, with therapeutic focus areas including immunology and infectious disease. Its work spans vaccine discovery through late-stage clinical development and regulatory approval.
- Who are MinervaX's investors?
- MinervaX's investors include Adjuvant Capital, Industrifonden, OrbiMed, Pureos Bioventures, Sanofi Ventures, Sunstone Capital, EQT Life Sciences, Novo Holdings and 1 more.